Cargando…

Correlation between serum matrix metalloproteinase and myocardial fibrosis in heart failure patients with reduced ejection fraction: A retrospective analysis

OBJECTIVE: A strong correlation exists between myocardial fibrosis and heart failure (HF). Myocardial fibrosis can be detected by cardiac magnetic resonance (CMR), which is a crucial noninvasive imaging method with high specificity and sensitivity. Matrix metalloproteinases (MMPs) are primary protea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Çelik, Ömer, Şahin, Ahmet Anıl, Sarıkaya, Serdar, Uygur, Begüm
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Kare Publishing 2020
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7724386/ https://www.ncbi.nlm.nih.gov/pubmed/33122477 http://dx.doi.org/10.14744/AnatolJCardiol.2020.54937

Ejemplares similares

Relationship between myocardial energy expenditure and postoperative ejection fraction in patients with severe mitral regurgitation
por: Ağuş, Hicaz Zencirkıran, et al.
Publicado: (2020)

Relationship between intrarenal renin-angiotensin activity and re-hospitalization in patients with heart failure with reduced ejection fraction
por: Örsçelik, Özcan, et al.
Publicado: (2018)

The prognostic value of altitude in patients with heart failure with reduced ejection fraction
por: Kaya, Ahmet, et al.
Publicado: (2019)

Adherence to guideline-directed medical and device Therapy in outpAtients with heart failure with reduced ejection fraction: The ATA study
por: Kocabaş, Umut, et al.
Publicado: (2020)

Effects of Kangdaxin on myocardial fibrosis in heart failure with preserved ejection fraction rats
por: Wu, Xiang, et al.
Publicado: (2022)

Twist/untwist parameters are promising evaluators of myocardial mechanic changes in heart failure patients with preserved ejection fraction
por: Zhang, Yi, et al.
Publicado: (2020)

Gender disparities in heart failure with mid-range and preserved ejection fraction: Results from APOLLON study
por: Özlek, Bülent, et al.
Publicado: (2019)

The concentration of interleukin-33 in heart failure with reduced ejection fraction
por: Anna Segiet, Oliwia, et al.
Publicado: (2019)

Reduced Lymphatic Reserve in Heart Failure With Preserved Ejection Fraction
por: Rossitto, Giacomo, et al.
Publicado: (2020)

Sildenafil and Kidney Function in Heart Failure with Preserved Ejection Fraction
por: Edmonston, Daniel, et al.
Publicado: (2023)

Ejection fraction, B‐type natriuretic peptide and risk of stroke and acute myocardial infarction among patients with heart failure
por: Greenberg, Barry, et al.
Publicado: (2019)

Matrix metalloproteinase-2, tissue inhibitor of matrix metalloproteinase-2, and transforming growth factor beta 1 in the aqueous humor and serum of patients with pseudoexfoliation syndrome
por: Kara, Selcuk, et al.
Publicado: (2014)

Biomarkers, myocardial fibrosis and co-morbidities in heart failure with preserved ejection fraction: an overview
por: Michalska-Kasiczak, Marta, et al.
Publicado: (2018)

A rare cause of mitral regurgitation after aortic valve replacement: Iatrogenic mitral valve perforation
por: Uygur, Begüm, et al.
Publicado: (2021)

Evaluation of serum neopterin, periostin, Tenascin‐C, tissue inhibitor of metalloproteinase-1 and matrix metalloproteinase-2 levels in obese pregnant women
por: Melekoğlu, Rauf, et al.
Publicado: (2022)

Association of muscular fitness with rehospitalization for heart failure with reduced ejection fraction
por: Lee, Chan Joo, et al.
Publicado: (2020)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Association of serum calcium and heart failure with preserved ejection fraction in patients with type 2 diabetes
por: Li, Junfeng, et al.
Publicado: (2016)

Prognostic significance of brain-derived neurotrophic factor levels in patients with heart failure and reduced left ventricular ejection fraction
por: Barman, Hasan Ali, et al.
Publicado: (2019)

Interleukin-33, matrix metalloproteinase-9, and tissue ınhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Imaging in Heart Failure with Preserved Ejection Fraction: A Multimodality Imaging Point of View
por: Ünlü, Serkan, et al.
Publicado: (2023)

Interleukin-16 Promotes Cardiac Fibrosis and Myocardial Stiffening in Heart Failure with Preserved Ejection Fraction
por: Tamaki, Shunsuke, et al.
Publicado: (2013)

Predictors of myocardial fibrosis and response to anti-fibrotic therapy in heart failure with preserved ejection fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Respiratory support in acute heart failure with preserved vs reduced ejection fraction
por: Metkus, Thomas S., et al.
Publicado: (2019)

Vaccine‐preventable disease hospitalized patients with heart failure with reduced ejection fraction
por: Del Cid Fratti, Juan, et al.
Publicado: (2022)

Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases in Extracellular Matrix Remodeling during Left Ventricular Diastolic Dysfunction and Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis
por: Krebber, Merle M., et al.
Publicado: (2020)

Erratum: Interleukin-33, matrix metalloproteinase-9, and tissue inhibitor of matrix metalloproteinase-1 in myocardial infarction
por: Guzel, Savas, et al.
Publicado: (2013)

Myocardial Contraction Fraction is Superior to Ejection Fraction in Predicting Functional Capacity in Patients with Heart Failure with Reduced Ejection Fraction
por: Abdellatif, Yasser A., et al.
Publicado: (2022)

The impact of heart rate on patients diagnosed with heart failure with mid-range ejection fraction
por: Xin, Yanguo, et al.
Publicado: (2019)

Relationship Between Urinary Angiotensinogen and Mortality in Patients with Heart Failure with Reduced Ejection Fraction
por: Örsçelik, Özcan, et al.
Publicado: (2023)

Eplerenone in patients with myocardial infarction and “mid‐range” ejection fraction: An analysis from the EPHESUS trial
por: Ferreira, João Pedro, et al.
Publicado: (2019)

Prognostic significance of medical therapy in patients with heart failure with reduced ejection fraction
por: Kocabaş, Umut, et al.
Publicado: (2023)

Impact of Myocardial Fibrosis on Cardiovascular Structure, Function and Functional Status in Heart Failure with Preserved Ejection Fraction
por: Lewis, Gavin A., et al.
Publicado: (2022)

Variability in Reassessment of Left Ventricular Ejection Fraction After Myocardial Infarction in the Acute Myocardial Infarction Quality Assurance Canada Study
por: Wilton, Stephen B., et al.
Publicado: (2021)

Structural and myocardial dysfunction in heart failure beyond ejection fraction
por: Severino, Paolo, et al.
Publicado: (2019)

Mode of Death Among Japanese Adults With Heart Failure With Preserved, Midrange, and Reduced Ejection Fraction
por: Kitai, Takeshi, et al.
Publicado: (2020)

Etiology-Dependent Impairment of Diastolic Cardiomyocyte Calcium Homeostasis in Heart Failure With Preserved Ejection Fraction
por: Frisk, Michael, et al.
Publicado: (2021)

Subclinical Risk Factors for Heart Failure With Preserved and Reduced Ejection Fraction Among Black Adults
por: Zhao, Li, et al.
Publicado: (2022)

Skeletal Muscle Mitochondrial Respiration and Exercise Intolerance in Patients With Heart Failure With Preserved Ejection Fraction
por: Scandalis, Lina, et al.
Publicado: (2023)

Predictive value of the age, creatinine, and ejection fraction score in patients with myocardial infarction with nonobstructive coronary arteries
por: Gao, Side, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_ft557j4vm2jhel0kcj31qpvnr5